Livagen
aka Lys-Glu-Asp-Ala
Immune Modulator
Mechanism
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala / KEDA) from the Khavinson short-peptide 'bioregulator' series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Marketed in Russia primarily as a food-supplement-grade cytomax; not FDA-approved in the US; research-use only.
Identification
Vendors selling Livagen
No vendor listings on file yet.
Research
No citations on file yet.